Patent applications published 9 February 2011
Selected patent applications from the weekly European Patents Bulletin
- Stable crystal modifications of DOPC
Merck Patent 2280691*
- Tablet comprising eprosartan mesylate
LEK Pharmaceuticals 2280692*
- Liquid and freeze-dried formulations
Ipsen Pharma 2280693*
- Humidity-resistant drug formulations and methods of preparation thereof
Dexcel Pharma Technologies 2280694*
- Hydroxytyrosol benefits mitochondria
DSM IP Assets 2280695*
- Modulators of the prostacyclin (PGI2) receptor useful for the treatment of diseases related thereto
Arena Pharmaceuticals 2280696*
- Oral liquid compsns of rhein or diacerein
Wockhardt Research Centre 2280697*
- Method for inhibiting the growth of bacteria
Mead Johnson Nutrition Co 2280698*
- Novel estrogen receptor ligands
Karo Bio 2280699*
- Combinations of dronedarone with at least one diuretic, and therapeutic use thereof
Sanofi-Aventis 2280700*
- Use of dronedarone for the preparation of a medicament for use in the prevention of cardiovascular hospitalisation or of mortality
Sanofi-Aventis 2280701*
- Use of dronedarone or a pharmaceutically acceptable salt thereof, for the preparation of a medicament for regulating the potassium level in the blood
Sanofi-Aventis 2280702*
- Use of NPY Y5 receptor antagonists for the prevention of psychostimulant and opioid abuse
University of Copenhagen 2280703*
- Oxymethylene aryl compounds and uses thereof
Metabolex 2280704*
- Novel compounds
Glaxo Group 2280705*
- Lipoprotein lipase activating compsns comprising benzene derivatives
Otsuka Pharmaceutical Factory 2280706*
- Alpha2B and alpha2C agonists
Allergan 2280707*
- MMP-2 and/or MMP-9 inhibitor
Otsuka Pharmaceutical 2280708*
- Treatment of hepatitis C virus infections with telaprevir (VX-950) in patients non-responsive to treatment with pegylated interferon-alpha-2A/2B and ribaviron
Vertex Pharmaceuticals 2280709*
- Novel treatment of heart diseases
Axiogenesis 2280710*
- Methods, dosage form and kits for administering ziprasidone without food
Pfizer 2280711*
- Fluocinolone formulations in a biodegradable polymer carrier
Warsaw Orthopedic; Medtronic 2280712*
- Methods and kits for the treatment of inflammatory bowel disorder conditions
Procter & Gamble 2280713*
- Compsns comprising anrnox-inhibitors for the inhibition of active oxygen species
Nu Skin International; NOX Technologies 2280714*
- Silicia for the inhibition of a protease
Ineos Healthcare 2280715*
- Agents and methods for treatment of anxiety disorders
Yeda Research and Development Co at the Weizmann Institute of Science 2280716*
- Therapeutic agent for anaerobic diseases
Anaeropharma Science 2280717*
- Extracts from plants of the tsuga genus and uses thereof in the treatment of inflammation, irritation and/or infection
Biopharmacopae Design International 2280718*
- Therapeutic use of at least one botulinum neurotoxin in the treatment of pain associated with diabetic neuropathy
Ipsen Pharma 2280719*
- Collagen-binding synthetic peptidoglycans, preparation and methods of use
Purdue Research Foundation 2280720*
- Indoleamine 2,3-dioxygenase based immunotherapy
Herlev Hospital 2280721*
- Method of treating degenerative diseases
Orthologic 2280722*
- Zona pellucisa binding peptides, expression vectors, compsns and methods for species-specific immunocontraception of animals
Auburn University 2280723*
- Compsns for treating an inflammatory autoimmune condition
TXCell 2280724*
- Antiviral nutraceutical
Marine Biotechnology Australia 2280726*
- Vaccine compsns for the treatment of dengue fever and uses thereof
Cytos Biotechnology 2280727*
- Combined measles-human papilloma vaccine
Cadila Healthcare 2280728*
- Method to design and uses of overlapping peptides for monitoring T-cell responses in HIV patients
Fondazione Centro San Raffaele del Monte Tabor; Helmholtz Zentrum München Deutsches Forschungszentrum für Gesundheit und Umwelt 2280730*
- Anti-human immunodeficiency antibodies and uses thereof
Tecnion Research and Development Foundation 2280731*
- Antibodies to granulocyte-macrophage colony-stimulating factor
Kalabios Pharmaceuticals 2280732*
- Maintenance therapy regimen for treating acne
Galderma Research & Development 2280733*
- Factor IX conjugates with extended half-lives
Celtic Pharma Peg 2280734*
- Agents for detecting and imaging cell death
Cambridge Enterprise 2280735*
- Fatty acid imides and uses thereof
Yissum Research Development Co of the Hebrew University of Jerusalem 2280934*
- 4-trimethylammonio-butyrates as CPT2 inhibitors
F Hoffmann-La Roche 2280935*
- Ether-amide type compounds, preparation method and uses
Rhodia Operations 2280936*
- Aliskiren monofumarate and processes for preparation thereof
Teva Pharmaceutical Industries 2280937*
- A process for preparing teriflunomide
Alembic 2280938*
- Novel N-(2-amino-phenyl)-acrylamides
F Hoffmann-La Roche 2280940*
- (Hetero)aryl cyclohexane derivatives
Grünenthal 2280941*
- Indolesulphonyl protecting groups for protection of guanidino and amino groups
Lonza 2280942*
- New substituted spiro(cycloalkyl-1,3’-indol)-2’(1’H)-one derivatives and their use as P38 mitogen-activated kinase inhibitors
Almirall 2280943*
- Process for the preparation of amides
Syngenta 2280944*
- Trisubstituted pyrazoles as acetylcholine receptor modulators
Janssen Pharmaceutica 2280945*
- 4-carboxamide indazole derivatives useful as inhibitors of P13-kinases
Glaxo Group 2280946*
- Production of 1,7’-dimethyl-2’-propyl-2,5’-bi-1H-benzimidazole
Boehringer Ingelheim International 2280947*
- Pyrimidine, pyridine and triazine derivatives as maxi-K channel openers
Mitsubishi Tanabe Pharma 2280948*
- Process for the preparation of benzo-fused heteroaryl sulphamates and crystalline form of N-((2S)-6-chloro-2,3-dihydro-L,4-benzodioxin-2-yl) methyl sulphamide
Janssen Pharmaceutica 2280950*
- Processes for the preparation of benzo-fused dioxin derivatives
Janssen Pharmaceutica 2280951*
- Thienopyridione derivatives as AMP-activated protein kinase (AMPK) activators
Merck Patent 2280952*
- New substituted indolin-2-one derivatives and their use as P38 mitogen-activated kinase inhibitors
Almirall 2280953*
